INTRODUCTION

Bill Grossman is the former Senior Vice President and Therapeutic Area Head of Oncology Clinical Development at Gilead Sciences Inc. overseeing the company’s Oncology portfolio (early and late-stage clinical development) and collaboration programs. Prior to that, he held several Chief Medical Officer roles including at Arcus Biosciences and Bellicum Pharmaceuticals. He has held additional leadership roles at Genentech/Roche, Merck, AbbVie, and Biothera.

Dr. Grossman has more than 25 years of experience in oncology, having begun his career as a practicing hematologist/oncologist with expertise in bone marrow transplants before moving into the biopharmaceutical industry. At the Medical College of Wisconsin, he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. Dr. Grossman currently serves as a Co-Founder and Head of R&D at Oncko, Inc. In addition, Dr. Grossman has served as an independent Board member and Strategic Pharmaceutical Advisor for several companies and is currently serving on the Board of Directors for Day One Biopharmaceuticals and the enGene Holdings Inc. Dr. Grossman is also currently serving as an interim/fractional CMO for several biotechs, and performs strategic, portfolio, and diligence reviews for venture capital firms and private equity organizations.

Dr. Grossman received his MD and PhD in Immunology from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical and post-doctoral training in both the Divisions of Pediatrics and Medicine at Washington University School of Medicine.